Active	Status	Sponsor type	Region	Phase	Filter
15 Active 1 Inactive 16 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Wong, Tamika
INTRAGO-II, NCT02685605: Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme	Active, not recruiting	3	314	Europe, Canada, US, RoW	Standard surgery, Intraoperative radiotherapy, IORT, Radiochemotherapy, Temozolomide	Universitätsmedizin Mannheim, Carl Zeiss Meditec AG, University of California, Los Angeles	Glioblastoma	06/24	06/26
SURVIVE, NCT05163080: SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma	Active, not recruiting	2	247	US	SurVaxM	MimiVax, LLC, Translational Drug Development, Merit	Newly Diagnosed Glioblastoma	08/24	08/24
NCT05986851: Azeliragon in MGMT Unmethylated Glioblastoma	Active, not recruiting	2	30	US	Azeliragon	Cantex Pharmaceuticals, Medpace, Inc.	Glioblastoma	09/24	06/25
FRONTIER, NCT05303467: A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM	Active, not recruiting	1	12	US	TheraSphere GBM, TheraSphere™ GBM Y-90 Glass Microspheres (TheraSphere GBM)	Boston Scientific Corporation	Glioblastoma Multiforme, Recurrent Glioblastoma	12/24	06/25
NCT06404034: Expanded Access to Gallium Maltolate (GaM)	Available	N/A		US	Gallium Maltolate, GaM	Imaging Biometrics, LLC, xCures	Glioblastoma, Refractory Glioblastoma, Glioblastoma Multiforme